Johnson & Johnson (JNJ) Q2 2026 earnings review
The STELARA Cliff is Dead; Guidance Raised as Pipeline Delivers
Johnson & Johnson delivered a definitive proof-of-concept quarter for its post-STELARA era. Total revenue grew 6.6% to $25.3B, and adjusted EPS grew 4.7% to $2.90, both beating expectations and prompting a full-year guidance raise across the board. The most telegraphed patent cliff in pharma history has been successfully neutralized: STELARA sales collapsed by 55%, yet the immunology portfolio successfully passed the baton to TREMFYA, which surged 72.5%. While the Innovative Medicine segment is firing on all cylinders, MedTech requires scrutiny as its growth rate is actively decelerating, contradicting management's broader acceleration narrative.
🐂 Bull Case
DARZALEX (+18.9% to $4.2B) and TREMFYA (+72.5% to $2.0B) are demonstrating exceptional, accelerating momentum. These assets are single-handedly carrying the company's growth profile through the biosimilar transition phase.
Management raised FY26 reported sales guidance to $101.1B (midpoint) and adjusted EPS to $11.68. Reaching the $100B+ threshold validates the company's long-term restructuring and spin-off of the consumer health division.
🐻 Bear Case
MedTech reported growth decelerated to 4.5% YoY, lagging the company average of 6.6%. The segment continues to face competitive pressures and international volume-based procurement (VBP) pricing headwinds.
Selling, marketing, and administrative expenses grew 9.2% YoY, outpacing the 6.6% revenue growth. This deleveraging is necessary to fund the TREMFYA and ICOTYDE launches, but limits immediate bottom-line expansion.
⚖️ Verdict: 🟢
Bullish. The existential threat of STELARA biosimilars is officially in the rearview mirror. With the new immunology pipeline scaling exponentially and guidance raised, the underlying engine is extremely healthy.
Key Themes
Immunology Pipeline Absorbs the STELARA Shock
Reversing the historical dread of patent cliffs, JNJ's immunology strategy is working flawlessly. While STELARA sales plummeted 55.2% to $740M due to biosimilars, TREMFYA sales accelerated violently, growing 72.5% YoY to $2.04B. Combined with the recent FDA approval of TREMFYA for stopping structural joint damage in active psoriatic arthritis, the immunology franchise is stable and expanding.
Oncology Franchise Remains an Unstoppable Engine
Oncology operational sales grew 16.1% YoY to $7.4B. The multiple myeloma dominance is clear: DARZALEX grew 18.9% to $4.2B, and CARVYKTI accelerated 49.4% to $657M. The recent regulatory data releases for RYBREVANT FASPRO in head/neck cancer and TALVEY plus DARZALEX in earlier-line multiple myeloma secure the pipeline's longevity through the 2030s.
Cardiovascular Expansion via Strategic M&A
Within MedTech, the Cardiovascular segment is stable and growing. Growth was spearheaded by recent acquisitions and innovations: Shockwave grew 14.6% to $335M, and Electrophysiology grew 4.4% to $1.53B. The global launch of the Shockwave C2 Aero Coronary IVL Catheter and the Dual Energy THERMOCOOL SMARTTOUCH SF Platform highlights rapid integration of acquired tech.
MedTech Narrative Contradicts Actual Data
Decelerating. Management has consistently pitched a 'MedTech acceleration' narrative heavily relying on CV acquisitions and the planned mid-2027 Orthopaedics spin-off. However, the data contradicts this: 26Q2 MedTech reported growth was just 4.5% YoY, decelerating from 7.7% in 26Q1, 7.5% in 25Q4, and 6.8% in 25Q3. The segment is growing significantly below the company average (6.6%), dragged down by macroeconomic policy (China VBP) and competitive legacy surgery markets.
SG&A Bloat Pressuring Operating Margins
Selling, marketing, and administrative expenses jumped 9.2% YoY to $6.43B, growing substantially faster than sales (+6.6%). This caused adjusted earnings before taxes to grow only 5.8%, indicating margin compression. While management previously guided for at least 50 bps of margin expansion in FY26, the current aggressive commercial spend for the TREMFYA expansion and upcoming ICOTYDE launch creates friction against that target.
Strategic Focus Sharpening via Portfolio Exits
The company continues to aggressively prune non-core assets. In Q2, restructuring expenses hit $200M (up from $0 reported similarly in prior quarter tables) largely related to asset impairments and site/supplier exits in both Innovative Medicine and MedTech Surgery divisions. This fits the broader, multi-year theme of focusing solely on high-margin, high-growth categories prior to the mid-2027 Orthopaedics split.
Surgical Robotics Paradigm Shift
JNJ announced pivotal clinical study results for a new soft-tissue surgical robotic system (OTTAVA) in upper abdominal procedures. This sets up a direct, long-awaited technological battle with Intuitive Surgical's monopoly, acting as a crucial future catalyst for the MedTech Surgery division ($2.6B in Q2, growing only 3.9%).
Other KPIs
Accelerating. Adjusted net earnings increased 5.7% YoY. While GAAP net earnings were flat (-0.1% YoY) at $5.53B, this was heavily skewed by $1.24B in intangible asset amortization and $267M in litigation-related expenses. The core operating earnings power remains highly resilient.
Accelerating significantly from the $6.21B generated in the first half of 2025. This robust cash conversion provides massive liquidity for the continued streak of dividend increases (now 64 consecutive years) and opportunistic M&A, such as the newly announced Firefly Bio acquisition.
Guidance
Accelerating. The midpoint of $101.1B implies 7.3% YoY growth, an increase from the April guidance of $100.3B-$101.3B (7.0% growth). This indicates management's confidence that the H1 momentum is durable and the STELARA headwinds are fully manageable.
Accelerating. The midpoint of $11.68 implies 8.2% YoY growth, raised from the prior guidance midpoint of $11.55 (7.1% growth). Despite the heavy SG&A and R&D spending observed in Q2, management expects enough leverage and mix-shift in H2 to drive substantial bottom-line expansion.
Key Questions
MedTech Disconnect
Your MedTech growth decelerated to 4.5% this quarter, significantly lagging the Innovative Medicine segment. How much of this drag is structural due to China VBP versus temporary market dynamics, and when do you expect the 'high single-digit' acceleration narrative to reflect in actual reported quarterly numbers?
Margin Leverage Constraints
SG&A expenses grew 9.2% this quarter, outpacing top-line growth to support major commercial launches. Is this elevated level of marketing spend the new normal structural run-rate required to compete in the post-STELARA immunology market, or do you expect SG&A leverage to return in 2027?
Robotics Commercialization Strategy
With the successful clinical data release for the OTTAVA surgical robotic system in upper abdominal procedures, how should investors model the commercial rollout timeline, and how will capital placement strategy differ from the established incumbent?